These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 35861550)
21. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306 [TBL] [Abstract][Full Text] [Related]
23. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro. Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382 [TBL] [Abstract][Full Text] [Related]
24. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor. Souza PFN; Amaral JL; Bezerra LP; Lopes FES; Freire VN; Oliveira JTA; Freitas CDT J Biomol Struct Dyn; 2022 Aug; 40(12):5493-5506. PubMed ID: 33427102 [TBL] [Abstract][Full Text] [Related]
25. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms. Ali A; Vijayan R Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162 [TBL] [Abstract][Full Text] [Related]
26. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites. Qiao B; Olvera de la Cruz M ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067 [TBL] [Abstract][Full Text] [Related]
27. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2. Basu A; Sarkar A; Maulik U Sci Rep; 2020 Oct; 10(1):17699. PubMed ID: 33077836 [TBL] [Abstract][Full Text] [Related]
28. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex. Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435 [TBL] [Abstract][Full Text] [Related]
29. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. Heurich A; Hofmann-Winkler H; Gierer S; Liepold T; Jahn O; Pöhlmann S J Virol; 2014 Jan; 88(2):1293-307. PubMed ID: 24227843 [TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Datta PK; Liu F; Fischer T; Rappaport J; Qin X Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005 [TBL] [Abstract][Full Text] [Related]
31. Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates. Alazmi M; Motwalli O J Mol Model; 2020 Nov; 26(12):338. PubMed ID: 33175236 [TBL] [Abstract][Full Text] [Related]
32. P21-activated kinase 1 (PAK1)-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degradation. Liu M; Lu B; Li Y; Yuan S; Zhuang Z; Li G; Wang D; Ma L; Zhu J; Zhao J; Chan CC; Poon VK; Chik KK; Zhao Z; Xian H; Zhao J; Zhao J; Chan JF; Zhang Y Signal Transduct Target Ther; 2023 Oct; 8(1):385. PubMed ID: 37806990 [TBL] [Abstract][Full Text] [Related]
33. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. Prajapat M; Shekhar N; Sarma P; Avti P; Singh S; Kaur H; Bhattacharyya A; Kumar S; Sharma S; Prakash A; Medhi B J Mol Graph Model; 2020 Dec; 101():107716. PubMed ID: 32866780 [TBL] [Abstract][Full Text] [Related]
34. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2. Verkhivker G Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276 [TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651 [TBL] [Abstract][Full Text] [Related]
36. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts. Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529 [TBL] [Abstract][Full Text] [Related]
37. Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants. Dehghani J; Movafeghi A; Mathieu-Rivet E; Mati-Baouche N; Calbo S; Lerouge P; Bardor M Mar Drugs; 2022 Oct; 20(11):. PubMed ID: 36354980 [TBL] [Abstract][Full Text] [Related]
38. Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes. Guo H; Hu BJ; Yang XL; Zeng LP; Li B; Ouyang S; Shi ZL J Virol; 2020 Sep; 94(20):. PubMed ID: 32699095 [TBL] [Abstract][Full Text] [Related]
39. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study. Shahbazi B; Mafakher L; Teimoori-Toolabi L J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180 [TBL] [Abstract][Full Text] [Related]
40. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2. Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]